Searched for
BIOCON LOAN
The 20 stocks mutual funds are buying with Rs 1 lakh crore to defy historic FII sellingIndian mutual funds are investing Rs 1.07 lakh crore in 20 key stocks to counter historic FII selling. They are focusing on large-cap priva...- S&P Global upgrades Biocon Biologics ratingsS&P Global Ratings on Wednesday upgraded Biocon Biologics ratings with a stable outlook.
- Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugsShares of Biocon Ltd rose 2% to Rs 361.25 on the BSE after its subsidiary, Biocon Biologics, received U.S. FDA approval for two denosumab b...
- Buy, Sell or Hold: Nuvama initiates coverage on Eureka Forbes; Religare Broking positive on RECBrokerages stay bullish: Nuvama starts Eureka Forbes with Buy (20% upside), Motilal Oswal reaffirms Biocon Buy (13% upside), Religare Broki...
- Biocon Biologics is planning to raise $950 million through overseas bondsBiocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its $1.2-billion debt from a...
- Biocon Biologics mulls raising up to Rs 4,500 crore in bondsThe company is in discussions with banks for the issuance, the people said, asking not to be named because the details are private. Funds f...
- Biocon denies plans to sell $1.5 billion generic API businessBiocon API business: Biocon has refuted claims of considering the sale of its generic active pharmaceutical ingredient (API) business, valu...
- Biocon weighs sale of $1.5 billion generic API businessThe Kiran Mazumdar-Shaw helmed company made a huge bet on biosimilars by acquiring a portfolio of drugs from global drug major Viatris for ...
- 'Biocon looking at options to cut debt taken for Viatris' business buy'"We are looking at a number of options to reduce that... I can say that you'll see the debt level coming down in the coming quarters," he s...
- Biocon Biologics may raise additional equity of $300 million in FY24 to pare debtBiocon Biologics plans to raise a further $300m by the end of FY24 in order to reduce its net debt, which peaked at $1.9bn in December 2022...
- Serum Institute to double investment in Biocon Biologics to $300 millionSerum Institute of Life Sciences (SILS) has converted a $150 million loan into equity, increasing its investment in Biocon Biologics. This ...
- Serum Life Sciences to double investments in Biocon Biologics to $300 million under new arrangementUnder the fresh terms of their strategic alliance, Serum Life Sciences will make an additional equity investment of $150 million through th...
- India's Serum to double investment in Biocon's unit to $300 mlnSerum Institute of Life Sciences is a unit of Serum Institute of India, the world's biggest vaccine maker. Under new terms of the alliance,...
- Biocon raises $1.2 billion green loan to fund purchase of Viatris unitBiocon agreed to meet certain sustainability targets that helped reduce the cost of the loan. According to sources, the loan came at a cost...
- Biocon completes $3.34 billion acquisition of Viatris's biosimilar businessTo fund the upfront payment, Biocon Biologics has secured $1.2 billion of Sustainability Linked Loan (SLL). The balance has been funded thr...
- Biocon Biologics secures regulatory approvals for acquisition of Viatris' biosimilar businessThe transaction with US-based Viatris required regulatory approvals from the Reserve Bank of India, Competition Commission of India and the...
- Hot Stocks: Brokerage view on ICICI Bank, L&T and Biocon"The stock is a re-rating candidate for a late-cycle beneficiary, but L&T's business currently lacks momentum. However, relative evaluation...
- Market movers: LIC shareholders lose Rs 77K crore in four days; Paytm gets 4% lift ahead of Q4 showLIC stock has fallen 13 per cent from its issue price of Rs 949 to Rs 826. In that process, shareholders of the company have lost over Rs 7...
- Biocon Biologics may close $3.34 billion Viatris deal in Q1Out of $2 billion, $800 million will come through equity infusion from existing investors including parent Biocon and others such as Serum ...
- Biocon Biologics to raise $1.2 billion overseas loan for Viatris dealBiocon Biologics, a unit of Biocon, is raising $1.2 billion via an offshore loan with the pharmaceutical company likely appointing HSBC, MU...
Load More
